Brokers Set Expectations for ELEV Q2 Earnings

Elevation Oncology, Inc. (NASDAQ:ELEV) – Equities researchers at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for Elevation Oncology in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will post earnings of ($0.20) per share for the quarter. The consensus estimate for Elevation Oncology’s current full-year earnings is ($0.84) per share. Leerink Partnrs also issued estimates for Elevation Oncology’s FY2025 earnings at ($0.85) EPS, FY2026 earnings at ($0.88) EPS and FY2027 earnings at ($1.10) EPS.

Several other research firms have also issued reports on ELEV. HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Elevation Oncology in a research report on Tuesday, January 14th. Stephens reaffirmed an “overweight” rating and issued a $5.00 price target on shares of Elevation Oncology in a research note on Friday, December 6th. JMP Securities reaffirmed a “market outperform” rating and set a $7.00 price objective on shares of Elevation Oncology in a research report on Thursday, December 19th. Finally, William Blair began coverage on shares of Elevation Oncology in a report on Friday, January 3rd. They set an “outperform” rating for the company. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Elevation Oncology presently has a consensus rating of “Buy” and an average price target of $7.20.

Elevation Oncology Stock Down 1.3 %

Shares of NASDAQ ELEV opened at $0.62 on Monday. Elevation Oncology has a 12-month low of $0.50 and a 12-month high of $5.83. The company has a quick ratio of 17.77, a current ratio of 17.77 and a debt-to-equity ratio of 0.45. The firm’s 50-day simple moving average is $0.65 and its 200 day simple moving average is $0.74. The company has a market cap of $36.83 million, a price-to-earnings ratio of -0.76 and a beta of 1.31.

Hedge Funds Weigh In On Elevation Oncology

Hedge funds and other institutional investors have recently modified their holdings of the business. Frazier Life Sciences Management L.P. lifted its stake in shares of Elevation Oncology by 102.6% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 5,993,579 shares of the company’s stock valued at $3,596,000 after acquiring an additional 3,035,000 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Elevation Oncology by 7.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,110,085 shares of the company’s stock valued at $666,000 after buying an additional 78,509 shares during the last quarter. Sphera Funds Management LTD. increased its stake in shares of Elevation Oncology by 227.2% in the third quarter. Sphera Funds Management LTD. now owns 1,079,762 shares of the company’s stock valued at $648,000 after buying an additional 749,762 shares during the period. State Street Corp raised its position in shares of Elevation Oncology by 13.5% during the third quarter. State Street Corp now owns 1,018,026 shares of the company’s stock worth $611,000 after acquiring an additional 120,993 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new position in Elevation Oncology during the 3rd quarter worth approximately $260,000. Institutional investors own 83.70% of the company’s stock.

About Elevation Oncology

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.